000 02680cam a2200349 a 4500
003 EG-GiCUC
005 20250223032522.0
008 200210s2020 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.08.09.Ph.D.2020.Mo.P
100 0 _aMohamed Ibrahim Mohamed Fahmy
245 1 4 _aThe possible neuroprotective effect of eprosartan and nateglinide in rats with cerebral ischemia- reperfusion injury /
_cMohamed Ibrahim Mohamed Fahmy ; Supervised Muhammad Farag Elyamany , Naglaa Assaf , Muhammed Abdullatif
246 1 5 _aالتأثير الوقائى المحتمل لدوائى إيبروسارتان و ناتيجلينايد على نقص التروية و إعادتها فى مخ الجرذان
260 _aCairo :
_bMohamed Ibrahim Mohamed Fahmy ,
_c2020
300 _a192 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology
520 _aIschemic stroke is a major cause of death and motor disabilities all over the world. It is associated with inflammatory, apoptotic, and oxidative responses. Nateglinide (NAT), an insulinotropic agent used for the treatment of type 2 diabetes mellitus, recently showed potential anti-inflammatory and anti-apoptotic effects. Eprosartan (EPRO) is an angiotensin type 1 receptor (AT1R) antagonist, used in treatment of hypertension which can also block AT1R of the brain and alleviate some of the pathophysiologic basis of stroke.The aim of our study was to elucidate the neuroprotective role of EPRO and NAT in the middle cerebral artery occlusion (MCAO)-induced stroke in rats. Ninety six male rats were divided to 6 groups (n = 16 in each group): the sham-operated group, sham receiving EPRO (60 mg/kg/day, p.o) group, sham receiving NAT (50 mg/kg/day, p.o) group, ischemia/reperfusion (IR) group, IR receiving EPRO group (60 mg/kg/day, p.o) and IR receiving NAT group (50 mg/kg/day, p.o). MCAO caused deficits in the motor functions of the rats with an increase of inflammation and apoptotic biomarkers has been observed in IR rats. Pretreatment with EPRO or NAT preserved some of the rats{u2019} behavioral and motor functions
530 _aIssued also as CD
653 4 _aEprosartan
653 4 _aInflammation
653 4 _aNateglinide
700 0 _aMuhammad Farag Elyamany ,
_eSupervisor
700 0 _aMuhammed Abdullatif ,
_eSupervisor
700 0 _aNaglaa Assaf ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aShimaa
_eCataloger
942 _2ddc
_cTH
999 _c76598
_d76598